Protagonist Therapeutics News

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)

TipRanks01:10 ET

Protagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising Pipeline

TipRanks21:55 ET

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates With Strategic Collaborations

Yahoo Finance21:04 ET

Protagonist GAAP EPS of $3.26, Revenue of $254.95M

Seeking Alpha17:47 ET

Protagonist Therapeutics | 10-Q: Quarterly report

Futu News16:59 ET · Announcements

Express News | Protagonist Therapeutics Q1 EPS $3.26, Sales $254.95M Beat $120.00M Estimate

Benzinga16:58 ET

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer

Accesswire16:10 ET

Express News | Protagonist Therapeutics Q1 Income From Operations USD 206.309 Million Vs. Ibes Estimate USD 36.9 Million

Reuters16:06 ET

Express News | Protagonist Therapeutics Q1 Basic EPS USD 3.41

Reuters16:06 ET

Express News | Protagonist Therapeutics Q1 Net Income USD 207.34 Million Vs. Ibes Estimate USD 39.3 Million

Reuters16:06 ET

Express News | Protagonist Therapeutics Q1 Operating Expenses USD 48.644 Million

Reuters16:06 ET

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-21

Accesswire16:05 ET

Multiple Insiders Sold Protagonist Therapeutics Shares Presenting Weak Signs For Investors

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. Knowing whether insiders are buying is usually mo

Simply Wall StMay 4 10:21 ET

We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon

Yahoo FinanceApr 29 08:22 ET

Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte, Italfarmaco, Lynk and Promedior

Yahoo FinanceApr 18 03:53 ET

Express News | Turnstone Biologics Appoints William Waddill to Its Board of Directors

Moomoo 24/7Apr 16 09:00 ET

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

You may think that with a price-to-sales (or "P/S") ratio of 26.3x Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in t

Simply Wall StApr 13 10:01 ET

Hemochromatosis Pipeline Insight Report 2024, Featuring Protagonist Therapeutics, Sirnaomics and Bond Biosciences

Yahoo FinanceApr 11 09:31 ET

All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

Yahoo FinanceApr 5 12:00 ET

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

Yahoo FinanceApr 3 01:52 ET